We analyzed the ability of interferon (IFN)-γ knockout mice (GKO) to reject a colon carcinoma transduced with interleukin (IL)-12 genes (C26/IL-12). Although the absence of IFN-γ impaired the early response and reduced the time to tumor onset in GKO mice, the overall tumor take rate was similar to that of BALB/c mice. In GKO mice, C26/IL-12 tumors had a reduced number of infiltrating leukocytes, especially CD8 and natural killer cells. Analysis of the tumor site, draining nodes, and spleens of GKO mice revealed reduced expression of IFN- inducible protein 10 and monokine induced by γ-IFN. Despite these defects, GKO mice that rejected C26/IL-12 tumor, and mice that were primed in vivo with irradiated C26/IL-12 cells, showed the same cytotoxic T lymphocyte activity but higher production of granulocyte/macrophage colony–stimulating factor (GM-CSF) as compared with control BALB/c mice. Treatment with monoclonal antibodies against GM-CSF abrogated tumor regression in GKO but not in BALB/c mice. CD4 T lymphocytes, which proved unnecessary or suppressive during rejection of C26/IL-12 cells in BALB/c mice, were required for tumor rejection in GKO mice. CD4 T cell depletion was coupled with a decline in GM-CSF expression by lymphocytes infiltrating the tumors or in the draining nodes, and with the reduction and disappearance of granulocytes and CD8 T cells, respectively, in tumor nodules. These results suggest that GM-CSF can substitute for IFN-γ in maintaining the CD8–polymorphonuclear leukocyte cross-talk that is a hallmark of tumor rejection.
Skip Nav Destination
Article navigation
1 July 1998
Article|
July 01 1998
Interferon γ–independent Rejection of Interleukin 12–transduced Carcinoma Cells Requires CD4+ T Cells and Granulocyte/Macrophage Colony–stimulating Factor
Chiara Zilocchi,
Chiara Zilocchi
From the *Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy; and the ‡Department of Experimental Medicine and Pathology, Second Chair of Pathology, University of Rome “La Sapienza”, 00100 Rome, Italy
Search for other works by this author on:
Antonella Stoppacciaro,
Antonella Stoppacciaro
From the *Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy; and the ‡Department of Experimental Medicine and Pathology, Second Chair of Pathology, University of Rome “La Sapienza”, 00100 Rome, Italy
Search for other works by this author on:
Claudia Chiodoni,
Claudia Chiodoni
From the *Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy; and the ‡Department of Experimental Medicine and Pathology, Second Chair of Pathology, University of Rome “La Sapienza”, 00100 Rome, Italy
Search for other works by this author on:
Mariella Parenza,
Mariella Parenza
From the *Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy; and the ‡Department of Experimental Medicine and Pathology, Second Chair of Pathology, University of Rome “La Sapienza”, 00100 Rome, Italy
Search for other works by this author on:
Nadia Terrazzini,
Nadia Terrazzini
From the *Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy; and the ‡Department of Experimental Medicine and Pathology, Second Chair of Pathology, University of Rome “La Sapienza”, 00100 Rome, Italy
Search for other works by this author on:
Mario P. Colombo
Mario P. Colombo
From the *Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy; and the ‡Department of Experimental Medicine and Pathology, Second Chair of Pathology, University of Rome “La Sapienza”, 00100 Rome, Italy
Search for other works by this author on:
Chiara Zilocchi
From the *Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy; and the ‡Department of Experimental Medicine and Pathology, Second Chair of Pathology, University of Rome “La Sapienza”, 00100 Rome, Italy
Antonella Stoppacciaro
From the *Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy; and the ‡Department of Experimental Medicine and Pathology, Second Chair of Pathology, University of Rome “La Sapienza”, 00100 Rome, Italy
Claudia Chiodoni
From the *Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy; and the ‡Department of Experimental Medicine and Pathology, Second Chair of Pathology, University of Rome “La Sapienza”, 00100 Rome, Italy
Mariella Parenza
From the *Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy; and the ‡Department of Experimental Medicine and Pathology, Second Chair of Pathology, University of Rome “La Sapienza”, 00100 Rome, Italy
Nadia Terrazzini
From the *Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy; and the ‡Department of Experimental Medicine and Pathology, Second Chair of Pathology, University of Rome “La Sapienza”, 00100 Rome, Italy
Mario P. Colombo
From the *Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy; and the ‡Department of Experimental Medicine and Pathology, Second Chair of Pathology, University of Rome “La Sapienza”, 00100 Rome, Italy
Address correspondence to Mario P. Colombo, Experimental Oncology D, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milano, Italy. Phone: 39-2-2390-252; Fax: 39-2-2362-692; E-mail: [email protected]
Received:
November 26 1997
Revision Received:
March 06 1998
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1998
J Exp Med (1998) 188 (1): 133–143.
Article history
Received:
November 26 1997
Revision Received:
March 06 1998
Citation
Chiara Zilocchi, Antonella Stoppacciaro, Claudia Chiodoni, Mariella Parenza, Nadia Terrazzini, Mario P. Colombo; Interferon γ–independent Rejection of Interleukin 12–transduced Carcinoma Cells Requires CD4+ T Cells and Granulocyte/Macrophage Colony–stimulating Factor . J Exp Med 1 July 1998; 188 (1): 133–143. doi: https://doi.org/10.1084/jem.188.1.133
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement